Osiris Therapeutics (NASDAQ: OSIR) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings and Valuation

This table compares Osiris Therapeutics and Aevi Genomic Medicine’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Osiris Therapeutics $86.60 million 2.31 $4.41 million N/A N/A
Aevi Genomic Medicine N/A N/A -$37.80 million ($1.02) -1.32

Osiris Therapeutics has higher revenue and earnings than Aevi Genomic Medicine.

Insider and Institutional Ownership

19.9% of Osiris Therapeutics shares are held by institutional investors. Comparatively, 21.0% of Aevi Genomic Medicine shares are held by institutional investors. 44.6% of Osiris Therapeutics shares are held by insiders. Comparatively, 24.8% of Aevi Genomic Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Osiris Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Osiris Therapeutics and Aevi Genomic Medicine, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osiris Therapeutics 0 0 0 0 N/A
Aevi Genomic Medicine 0 1 1 0 2.50

Aevi Genomic Medicine has a consensus target price of $4.25, indicating a potential upside of 214.81%. Given Aevi Genomic Medicine’s higher possible upside, analysts clearly believe Aevi Genomic Medicine is more favorable than Osiris Therapeutics.

Profitability

This table compares Osiris Therapeutics and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osiris Therapeutics -2.60% -3.13% -2.59%
Aevi Genomic Medicine N/A -125.94% -106.93%

Summary

Osiris Therapeutics beats Aevi Genomic Medicine on 6 of the 10 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Stock Ratings for Osiris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics Inc. and related stocks with our FREE daily email newsletter.